导管原位癌检出方式与复发结局:乳腺X线与乳腺超声检出的多中心复发比较研究
这项多中心回顾性研究纳入844例接受治疗的无症状导管原位癌女性,术前均有乳腺X线和乳腺超声检查。25例(3.0%)发生复发,超声检出组5年和10年无复发生存率显著低于乳腺X线检出组(p=0.011)。超声作为检出方式(HR 4.451)和HER2阳性(HR 4.036)与复发显著相关。
要点
- 超声检出导管原位癌的5年和10年无复发生存率显著低于乳腺X线检出者(p=0.011)。
- 年龄<50岁或乳腺X线致密乳腺患者中,超声检出者无复发生存率亦显著更低(p=0.002和0.002)。
- 超声作为检出方式(HR 4.451)和HER2阳性(HR 4.036)与复发显著相关。
核心结论
- 超声作为检出方式和HER2阳性与接受治疗的无症状导管原位癌患者复发显著相关。
研究设计与样本
- 多中心回顾性研究,纳入844例接受治疗的无症状导管原位癌女性,术前均有乳腺X线和乳腺超声检查。
诊断标准与关键数值
- 超声检出组5年和10年无复发生存率显著低于乳腺X线检出组(p=0.011)。
- 年龄<50岁患者中,超声检出组5年和10年无复发生存率显著低于乳腺X线检出组(p=0.002)。
- 乳腺X线致密乳腺患者中,超声检出组5年和10年无复发生存率显著低于乳腺X线检出组(p=0.002)。
- 超声作为检出方式与复发显著相关(HR 4.451;95%CI 1.530,12.950;p=0.006)。
- HER2阳性与复发显著相关(HR 4.036;95%CI 1.438,11.330;p=0.008)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
The purpose of this study was to determine whether disease recurrence and intrinsic characteristics of ductal carcinoma in situ (DCIS) are associated with the imaging method of detection in asymptomatic women. This multicenter, retrospective study included 844 women treated for asymptomatic DCIS who had pre-operative mammography and breast ultrasonography (US) studies available. Of the 844 women, 25 (3.0%) developed recurrences. Patients in the US group had significantly lower 5- and 10-y recurrence-free survival (RFS) rates compared with patients in the mammography group (p = 0.011). US-detected DCIS showed significantly lower 5-and 10-y RFS rates compared with mammography-detected DCIS in patients <50 y or with mammographically dense breasts (p = 0.002 and 0.002, respectively). US as the detection modality (hazard ratio [HR]: 4.451; 95% confidence interval [CI]: 1.530, 12.950; p = 0.006) and HER2 positivity (HR: 4.036; 95% CI: 1.438; 11.330; p = 0.008) were significantly associated with recurrence. We concluded that US as the detection modality and HER2 positivity were significantly associated with recurrence in patients treated for asymptomatic DCIS.
引用
- Yoon JH, Han K, Koh J, et al. Outcomes of Ductal Carcinoma In Situ According to Detection Modality: A Multicenter Study Comparing Recurrence Between Mammography and Breast US. Ultrasound Med Biol. 2019. PMID: 31351671. doi:10.1016/j.ultrasmedbio.2019.06.420
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。